Amphastar at Jefferies Conference: Strategic Focus on Growth

At the Jefferies Global Healthcare Conference 2025, Amphastar Pharmaceuticals (NASDAQ:AMPH) outlined plans to achieve double-digit sales growth, driven by complex generic injectables, proprietary products Baqsimi and Primatene Mist, and anticipated FDA approvals. While Q1 2025 revenues were flat with a slight earnings decline due to increased R&D, the company expects growth from Baqsimi, projecting peak sales of $250-275 million, and anticipates two ANDA approvals by year-end, including the inhalation product AMP007 expected to launch in Q4 2025 priced 30% below the brand.

Analysis

Amphastar Pharmaceuticals (AMPH) outlined its strategy at the Jefferies Global Healthcare Conference 2025 to rejuvenate growth, targeting a return to double-digit sales increases in 2026 after projecting flat revenues for 2025. The company's Q1 2025 results reflected this stagnation with flat year-over-year revenues and a slight earnings decline, attributed to heightened R&D spending and competitive pricing pressures on established products like glucagon kits, which are constricting gross margins. Key growth drivers identified include the proprietary intranasal glucagon Baqsimi, acquired from Eli Lilly and targeting peak sales between $250 million and $275 million, and Primatene Mist, an OTC asthma medication; Baqsimi is guided for high single-digit script growth in 2025 and Primatene Mist for high single-digit sales growth, with Baqsimi expecting a significant Q3 sales uplift due to back-to-school seasonality despite flat Q1 net sales linked to acquisition accounting. Further impetus is anticipated from the pipeline, with two Abbreviated New Drug Application (ANDA) approvals expected by year-end 2025: AMP002, a complex generic injectable where recent FDA correspondence has been favorable, and AMP007, an inhalation product with no current generic competitors, slated for a Q4 2025 launch at an anticipated 30% discount to the brand. While new tariffs on Chinese APIs are projected to add approximately $500,000 in quarterly costs, Amphastar views this as manageable, partly due to its U.S.-based finished product manufacturing and substantial existing API inventory.

Key Decisions for Investors

• Investors should monitor Baqsimi's script volumes and revenue trajectory, especially the Q3 seasonal performance, as this is crucial for achieving 2025 targets and setting the stage for future growth.
• Focus on the FDA approval outcomes and launch execution for pipeline products AMP002 and particularly AMP007 by year-end 2025, as these are key to realizing the company's projected return to double-digit sales growth in 2026.
• Assess Amphastar's ability to manage gross margin pressures from competition and increased R&D spending, alongside the impact of API tariffs, to ensure a balance between revenue expansion and profitability.